Geron (NASDAQ:GERN) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of Geron (NASDAQ:GERN) in a report published on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $10.00 target price on the biopharmaceutical company’s stock.

Several other research firms also recently commented on GERN. Needham & Company LLC reiterated a buy rating and issued a $5.00 price target on shares of Geron in a research report on Thursday, April 11th. The Goldman Sachs Group increased their price target on shares of Geron from $4.00 to $5.00 and gave the company a buy rating in a report on Friday, March 15th. Finally, Wedbush reiterated an outperform rating and issued a $6.00 price target on shares of Geron in a report on Wednesday, April 10th.

Geron Price Performance

Geron stock opened at $4.14 on Monday. Geron has a 1 year low of $1.64 and a 1 year high of $4.30. The company’s 50 day simple moving average is $2.89 and its 200-day simple moving average is $2.31. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -12.55 and a beta of 0.61. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.16 and a current ratio of 3.16.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. During the same quarter in the previous year, the business posted ($0.10) EPS. The firm’s revenue was down 77.7% on a year-over-year basis. As a group, equities research analysts expect that Geron will post -0.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Geron in the third quarter valued at $40,000. Commonwealth Equity Services LLC lifted its holdings in Geron by 20.0% in the third quarter. Commonwealth Equity Services LLC now owns 218,297 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 36,358 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Geron by 19.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,023 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 16,992 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Geron by 29.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 73,470 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 16,653 shares during the period. Finally, Chicago Partners Investment Group LLC lifted its holdings in Geron by 40.2% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 29,866 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 8,557 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.